Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Myasthenia Gravis
Biotech
J&J posts adolescent myasthenia gravis data on $6B FcRn blocker
J&J has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with gMG to the case for its near-approval FcRn blocker.
Nick Paul Taylor
Oct 15, 2024 9:25am
J&J files for FDA approval of $6.5B autoimmune drug
Aug 29, 2024 8:57am
Cartesian claims autoimmune CAR-T win after changing endpoint
Jul 2, 2024 7:56am
J&J posts pivotal data, prepares to crash argenx, UCB's party
Jul 1, 2024 6:00am
Immunovant promotes next-gen FcRn drug in race to rival Vyvgart
May 30, 2024 7:02am
Takeda culls cancer, gut and inflammation drugs in R&D rethink
May 9, 2024 5:13am
